



**Australian Government**  
**Repatriation Medical Authority**

**Amendment Statement of Principles**  
**concerning**  
**HYPOPITUITARISM**  
**(Reasonable Hypothesis)**  
**(No. 53 of 2022)**

---

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

Dated 29 April 2022

The Common Seal of the  
Repatriation Medical Authority  
was affixed to this instrument  
at the direction of:

Professor Terence Campbell AM  
Chairperson

# Contents

1	Name .....	3
2	Commencement .....	3
3	Authority .....	3
4	Amendment.....	3

## 1 Name

This is the Amendment Statement of Principles concerning *hypopituitarism (Reasonable Hypothesis)* (No. 53 of 2022).

## 2 Commencement

This instrument commences on 30 May 2022.

## 3 Authority

This instrument is made under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

## 4 Amendment

The Statement of Principles concerning *hypopituitarism (Reasonable Hypothesis)* (No. 11 of 2019) (Federal Register of Legislation No. F2019L00009) is amended in the following manner:

Section	Amendment
9(16)	<p><i>Replace the existing factor in subsection 9(16) with the following:</i></p> <p>taking an immune checkpoint inhibitor or an interferon within the one year before the clinical onset of hypopituitarism;</p> <p>Note: <b><i>immune checkpoint inhibitor</i></b> is defined in the Schedule 1 - Dictionary.</p>
9(34)	<p><i>Replace the existing factor in subsection 9(34) with the following:</i></p> <p>taking an immune checkpoint inhibitor or an interferon within the one year before the clinical worsening of hypopituitarism;</p> <p>Note: <b><i>immune checkpoint inhibitor</i></b> is defined in the Schedule 1 - Dictionary.</p>
<i>Schedule 1 – Dictionary</i>	<p><i>Replace the existing definition of "immune checkpoint inhibitor" with the following:</i></p> <p><b><i>immune checkpoint inhibitor</i></b> means a form of cancer immunotherapy that uses monoclonal antibodies targeting the immune checkpoint proteins. Examples include ipilimumab, tremelimumab, nivolumab and pembrolizumab.</p>